| Browse All

BioLineRx Ltd. (BLRX)

Healthcare | Biotechnology | Hevel Modi'in, Israel | NasdaqCM
2.45 USD +0.06 (2.510%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 2.41 -0.04 (-0.038%) ⇩ (April 17, 2026, 7:20 p.m. EDT)

Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ★☆☆☆☆
Hot Take | April 19, 2026, 12:01 a.m. EDT

High-risk speculative biotech with deteriorating fundamentals (catalyst trust depleting) and severe price decay (+27% over 6 months). While recent partnership news offers a tiny glimmer of hope, the technical setup is broken with significant distance from moving averages; this is not a buy opportunity absent a major binary event.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.094325
AutoARIMA0.147709
AutoETS0.148189
MSTL0.148333

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 41%
H-stat 33.54
Ljung-Box p 0.000
Jarque-Bera p 0.173
Excess Kurtosis -1.14
Attribute Value
Sector Healthcare
Debt to Equity Ratio 43.478
Market Cap 11,023,557
Trailing P/E Infinity
Forward P/E -3.66
Beta 0.48
Profit Margins -99.58%
Website https://www.biolinerx.com

As of April 19, 2026, 12:01 a.m. EDT: Options activity is extremely sparse with negligible volume across all expirations. Call Open Interest (OI) is concentrated at out-of-the-money strikes (5.0 and 6.0 for May '26), while Put OI is completely absent. This near-total lack of short-side positioning suggests no significant speculative beta flow is currently pricing in downside risk, despite the stock's technical deterioration. Implied Volatility data is missing, indicating low spectral interest.


Info Dump

Attribute Value
52 Week Change -0.15517241
Address1 Modi’in Technology Park
Address2 2 HaMa’ayan Street
All Time High 4,122.0
All Time Low 2.15
Ask 2.48
Ask Size 1
Average Analyst Rating 1.0 - Strong Buy
Average Daily Volume10 Day 10,920
Average Daily Volume3 Month 14,021
Average Volume 14,021
Average Volume10Days 10,920
Beta 0.482
Bid 2.39
Bid Size 1
Book Value 4.2
City Hevel Modi'in
Compensation As Of Epoch Date 1,767,139,200
Country Israel
Crypto Tradeable 0
Currency USD
Current Price 2.45
Current Ratio 1.953
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 2.4601
Day Low 2.3489
Debt To Equity 43.478
Dividend Date 1,563,148,800
Earnings Call Timestamp End 1,774,269,000
Earnings Call Timestamp Start 1,774,269,000
Earnings Timestamp 1,774,269,000
Earnings Timestamp End 1,779,885,000
Earnings Timestamp Start 1,779,885,000
Ebitda -10,060,000
Ebitda Margins 0.0
Enterprise To Ebitda -635.28
Enterprise To Revenue 5,416.032
Enterprise Value 6,390,918,144
Eps Current Year -1.09
Eps Forward -0.67
Eps Trailing Twelve Months 0.0
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 972 8 642 9101
Fifty Day Average 2.6152
Fifty Day Average Change -0.1652
Fifty Day Average Change Percent -0.06316916
Fifty Two Week Change Percent -15.517241
Fifty Two Week High 7.77
Fifty Two Week High Change -5.3199997
Fifty Two Week High Change Percent -0.68468463
Fifty Two Week Low 2.15
Fifty Two Week Low Change 0.29999995
Fifty Two Week Low Change Percent 0.13953486
Fifty Two Week Range 2.15 - 7.77
Financial Currency USD
First Trade Date Milliseconds 1,311,773,400,000
Float Shares 2,498,157,749
Forward Eps -0.67
Forward P E -3.6567163
Free Cashflow -3,875,250
Full Exchange Name NasdaqCM
Full Time Employees 20
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.80508006
Gross Profits 950,000
Has Pre Post Market Data 1
Held Percent Insiders 0.03995
Held Percent Institutions 0.01097
Implied Shares Outstanding 4,499,411
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,738,195,200
Last Split Factor 1:40
Long Business Summary BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Long Name BioLineRx Ltd.
Market us_market
Market Cap 11,023,557
Market State PREPRE
Max Age 86,400
Message Board Id finmb_5015080
Most Recent Quarter 1,767,139,200
Net Income To Common -1,175,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 11,319,264
Number Of Analyst Opinions 2
Open 2.39
Operating Cashflow -8,074,000
Operating Margins -17.45361
Payout Ratio 0.0
Phone 972 8 642 9100
Post Market Change -0.037500143
Post Market Change Percent -1.5306181
Post Market Price 2.4125
Post Market Time 1,776,468,026
Previous Close 2.39
Price Eps Current Year -2.2477064
Price Hint 4
Price To Book 0.5833334
Price To Sales Trailing12 Months 9.341997
Profit Margins -0.99575996
Quick Ratio 1.76
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.0
Region US
Regular Market Change 0.059999943
Regular Market Change Percent 2.5104578
Regular Market Day High 2.4601
Regular Market Day Low 2.3489
Regular Market Day Range 2.3489 - 2.4601
Regular Market Open 2.39
Regular Market Previous Close 2.39
Regular Market Price 2.45
Regular Market Time 1,776,456,000
Regular Market Volume 7,930
Return On Assets -0.16112
Return On Equity -0.110089995
Revenue Growth -0.983
Revenue Per Share 0.0
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 4,351,357
Shares Percent Shares Out 0.0376
Shares Short 163,818
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 169,422
Short Name BioLineRx Ltd.
Short Percent Of Float 0.0377
Short Ratio 11.26
Source Interval 15
Symbol BLRX
Target High Price 23.0
Target Low Price 12.0
Target Mean Price 17.5
Target Median Price 17.5
Total Cash 20,876,000
Total Cash Per Share 0.008
Total Debt 10,150,000
Total Revenue 1,180,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps 0.0
Trailing P E Infinity
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 3.36055
Two Hundred Day Average Change -0.9105499
Two Hundred Day Average Change Percent -0.27095264
Type Disp Equity
Volume 7,930
Website https://www.biolinerx.com
Zip 7,177,871